STEPHANIE CALLAWAY: Open Payments
NPI 1730616921 · FORT WORTH, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,847 in 98 payments from 21 companies in 2025. Trend: 2023 $1,220 · 2024 $1,314 · 2025 $1,847
Food & beverage: $1,847
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 10 | $215 |
| ABBVIE INC. | 14 | $206 |
| Lilly USA, LLC | 11 | $200 |
| Novo Nordisk Inc | 9 | $188 |
| PFIZER INC. | 11 | $174 |
| GlaxoSmithKline, LLC. | 9 | $154 |
| Astellas Pharma US Inc | 5 | $93 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $92 |
| Abbott Laboratories | 3 | $77 |
| Corcept Therapeutics | 2 | $69 |
Products named: JARDIANCE, QULIPTA, ELIQUIS, AIRSUPRA, MOUNJARO, TRELEGY ELLIPTA, Veozah, TRINTELLIX.
Industry payments across TX — which companies pay providers there.
